THIS WEBSITE IS INTENDED FOR U.S. RESIDENTS ONLY
FOR HEALTHCARE PROFESSIONALS
THIS WEBSITE IS INTENDED FOR U.S. RESIDENTS ONLY | FOR HEALTHCARE PROFESSIONALS

CHOOSE A BOWEL PREP THAT FOLLOWS THE GUIDELINES1,2

Review Guidelines

The US Multi-Society Task Force on Colorectal Cancer* recently raised the standard for bowel prep adequacy from ≥85% to ≥90%. The guidelines have been put into place to ensure that the medicines you take meet medical standards for effectiveness.1,2

So whether it’s a liquid or tablet, you can feel confident either bowel prep will meet or exceed experts’ recommendations.1,2

Choose a Bowel Prep That Exceeds the ≥90% Adequacy Target1-5

99%
of patients achieved prep adequacy
with SUFLAVE®3
97%
of patients achieved prep adequacy
with SUTAB®4,5

Choose a Bowel Prep That’s Easy to Take3-5

87%
of patients found SUFLAVE® tolerable
to very easy to consume3
79%
of patients found SUFLAVE® neutral
to very pleasant3
  • The majority of patients said SUFLAVE®
    tastes like a sports drink    3
91%
of patients in one pivotal trial rated SUTAB®
as tolerable to very easy to consume4†
78%
of patients in one pivotal trial would request
SUTAB® again for a future colonoscopy5†

Your Bowel Prep, Your Choice

Study Design for SUFLAVE®3,6: This phase 3 trial was conducted in multiple sites. Of the 500 subjects who enrolled, 450 were evaluable for efficacy analyses. The primary endpoint was the percentage of subjects with successful cleansing, which was defined as a rating of excellent or good as assigned by the local endoscopist utilizing the US FDA Bowel Prep Scoring Scale. Secondary endpoints included prep adequacy, cecal intubation and adenoma detection rates, procedure duration, and intraprocedural water. Independent central readers also reviewed all colonoscopy videos and provided a global cleansing grade, as well as segmental grades, on insertion and withdrawal using a 4-point scale of excellent, good, fair, and poor. The goal of the study was to establish non-inferiority of SUFLAVE® to SUPREP® Bowel Prep Kit, using a 10% margin.
Study Design for SUTAB®5: This phase 3 trial was conducted in 22 US sites. Of the 620 subjects who enrolled, 548 patients were evaluable for efficacy analyses. The primary endpoint was the percentage of subjects with successful cleansing, which was based on the US FDA Bowel Prep Scoring Scale, the goal of which was to determine non-inferiority against MoviPrep®. Safety follow-up visits were required 24-48 hours after colonoscopy and on days 7 and 30 if adverse events or lab abnormalities were indicated. The primary endpoint of non-inferiority was met.
*
US Multi-Society Task Force on Colorectal Cancer is comprised of the American College of Gastroenterology®, the American Gastroenterological Association, and the American Society for Gastrointestinal Endoscopy®. Their goal is to ensure that patients receive the correct procedure and diagnosis, that therapy is properly performed, and that all this is accomplished with minimum risk. Visit https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3104386/ to learn more.
†
Patients completed a preference questionnaire following completion of study drug to capture their perceptions of the preparation experience. This questionnaire has not undergone formal validation.
MoviPrep® is a registered trademark of Velinor AG.
IMPORTANT SAFETY INFORMATION FOR SUFLAVE®
INDICATION

SUFLAVE® (polyethylene glycol 3350, sodium sulfate, potassium chloride, magnesium sulfate, and sodium chloride for oral solution) is an osmotic laxative indicated for cleansing of the colon in preparation for colonoscopy in adults.

DOSAGE AND ADMINISTRATION

A low residue breakfast may be consumed on the day before colonoscopy, followed by clear liquids up to 2 hours prior to colonoscopy. Administration of two doses of SUFLAVE® are required for a complete preparation for colonoscopy. Each bottle must be reconstituted with water before ingestion. Each bottle and one flavor enhancing packet are equivalent to one dose. An additional 16 ounces of water must be consumed after each dose. Stop consumption of all fluids at least 2 hours before the colonoscopy.

CONTRAINDICATIONS

Use is contraindicated in the following conditions: gastrointestinal obstruction or ileus, bowel perforation, toxic colitis or toxic megacolon, gastric retention, hypersensitivity to any ingredient in SUFLAVE®.

WARNINGS AND PRECAUTIONS

Risk of fluid and electrolyte abnormalities: Encourage adequate hydration, assess concurrent medications and consider laboratory assessments prior to and after each use; Cardiac arrhythmias: Consider pre-dose and post-colonoscopy ECGs in patients at increased risk; Seizures: Use caution in patients with a history of seizures and patients at increased risk of seizures, including medications that lower the seizure threshold; Colonic mucosal ulcerations: Consider potential for mucosal ulcerations when interpreting colonoscopy findings in patients with known or suspected inflammatory bowel disease; Patients with renal impairment or taking concomitant medications that affect renal function: Use caution, ensure adequate hydration and consider laboratory testing; Suspected GI obstruction or perforation: Rule out the diagnosis before administration; Patients at risk for aspiration: Observe during administration; Hypersensitivity reactions, including anaphylaxis: Inform patients to seek immediate medical care if symptoms occur.

ADVERSE REACTIONS

Most common adverse reactions (≥2%) are: nausea, abdominal distension, vomiting, abdominal pain, and headache.

DRUG INTERACTIONS

Drugs that increase risk of fluid and electrolyte imbalance.

IMPORTANT SAFETY INFORMATION FOR SUTAB®

INDICATION
SUTAB® (sodium sulfate, magnesium sulfate, potassium chloride) tablets for oral use is an osmotic laxative indicated for cleansing of the colon in preparation for colonoscopy in adults.

DOSAGE AND ADMINISTRATION
A low residue breakfast may be consumed. After breakfast, only clear liquids may be consumed until after the colonoscopy. Administration of two doses of SUTAB® (24 tablets) are required for a complete preparation for colonoscopy. Twelve (12) tablets are equivalent to one dose. Each SUTAB® bottle contains a desiccant. Remove and discard the desiccant from both bottles the evening prior to the colonoscopy. Water must be consumed with each dose of SUTAB® and additional water must be consumed after each dose. Complete all SUTAB® tablets and required water at least 2 hours before colonoscopy.

CONTRAINDICATIONS
Use is contraindicated in the following conditions: gastrointestinal obstruction or ileus, bowel perforation, toxic colitis or toxic megacolon, gastric retention, hypersensitivity to any ingredient in SUTAB®.

WARNINGS AND PRECAUTIONS
Risk of fluid and electrolyte abnormalities: Encourage adequate hydration, assess concurrent medications and consider laboratory assessments prior to and after each use; Cardiac arrhythmias: Consider pre-dose and post-colonoscopy ECGs in patients at increased risk; Seizures: Use caution in patients with a history of seizures and patients at increased risk of seizures, including medications that lower the seizure threshold; Patients with renal impairment or taking concomitant medications that affect renal function: Use caution, ensure adequate hydration and consider laboratory testing; Colonic mucosal ulcerations: Consider potential for mucosal ulcerations when interpreting colonoscopy findings in patients with known or suspected inflammatory bowel disease. Suspected GI obstruction or perforation: Rule out the diagnosis before administration. Hypersensitivity reactions, including anaphylaxis: Inform patients to seek immediate medical care if symptoms occur. Risk of Gastrointestinal Complications with Ingestion of Desiccant: Postmarketing reports of ingestion of the desiccant along with SUTAB® tablets has been reported and may be associated with risk of gastrointestinal complications and/or choking.

ADVERSE REACTIONS
Most common gastrointestinal adverse reactions are: nausea, abdominal distension, vomiting, and upper abdominal pain.

DRUG INTERACTIONS
Drugs that increase risk of fluid and electrolyte imbalance.

References: 1. Rex DK, Anderson JC, Butterfly LF, et al. Quality indicators for colonoscopy. Gastrointest Endosc. 2024;100(3):352-381. doi:10.1016/j.gie.2024.04.2905 2. Johnson DA, Barkun AN, Cohen LB, et al. Optimizing bowel preparation quality for colonoscopy: consensus recommendations by the US Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2025;00:1-27. doi.org/10.14309/ajg.0000000000003287 3. Bhandari R, Goldstein M, Mishkin DS, et al. Comparison of a novel, flavor-optimized, polyethylene glycol and sulfate bowel preparation with oral sulfate solution in adults undergoing colonoscopy. J Clin Gastroenterol. 2023;57(9):920-927. doi:10.1097/MCG.0000000000001894 4. Di Palma JA, Bhandari R, Cleveland M, et al. A safety and efficacy comparison of a new sulfate-based tablet bowel preparation versus a PEG and ascorbate comparator in adult subjects undergoing colonoscopy. Am J Gastroenterol. 2021;116(2):319-328. doi:10.14309/ajg.0000000000001020 5. SUFLAVE® [package insert]. Braintree, MA: Braintree Laboratories, Inc. 6. SUTAB® [package insert]. Braintree, MA: Braintree Laboratories, Inc. 7. National Cancer Institute. Cancer stat facts: colorectal cancer. Available at https://seer.cancer.gov/statfacts/html/colorect.html. Accessed June 16, 2023. 8. American College of Gastroenterology. Colorectal cancer: you can prevent it. Available at: https://webfiles.gi.org/links/committees/Public%20Relations/2021CRC-infographic.pdf. Accessed June 16, 2023. 9. American College of Gastroenterology. You can prevent colorectal cancer: don’t let COVID-19 stop you. Available at https://webfiles.gi.org/links/committees/Public%20Relations/21CRC-COVID19-Brochure-Trifold-FINAL.pdf. Accessed June 16, 2023. 10. American College of Gastroenterology. 45 is the new 50! Available at https://webfiles.gi.org/links/committees/PublicRelations/22CRC-45new50-Brochure-Trifold.pdf. Accessed June 12, 2025.

Please see SUFLAVE.com and SUTAB.com for Full Prescribing Information and Medication Guides.
Braintree
© 2025 Braintree Laboratories, Inc. All rights reserved. 550-993-v1 August 2025
Please see Full Prescribing Information and Medication Guides for SUFLAVE and SUTAB.